For a better experience, click the icon above to turn off Compatibility Mode, which is only for viewing older websites.
August 25, 2020
Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announces the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of RAD52, a critical molecule involved in the DNA damage response (DDR) pathway. The agreement expands Rain’s targeted oncology pipeline to include synthetic lethal strategies for the treatment of cancers associated with mutations in the DDR pathway, including breast and ovarian cancers characterized by BRCA1/2 mutations.
August 1, 2020
Alex Mazin wins DOD and NIH grants totaling $2.844 Million to support his development of Inhibitors of RAD52 as a Therapy Against BRCA-Deficient cancers.